Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus R-CHOP in MCD subtype DLBCL
NCT05234684Phase 3Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Orelabrutinib + R-CHOP with Placebo + R-CHOP (2 arms). Primary endpoints: Progression Free Survival and Complete Response Rate by Independent Review Committee. Started Nov 2022; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05234684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234684.